PT
Prescient Therapeutics Limited
PTX.AX · ASX
$0.07 -4.41% (-$0.00)
1M -20.00%
Market Cap $71.5M
P/E Ratio -
Div. Yield -
ROE 48.12%
Bulios Fair Price
$0.04
38.5% downside
Trenutna cena
$0.065
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica PTX.AX trenutno precenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Weak
1/9Valuation
37 /100
Fair P/B 5.04x
P/E N/A
EV/FFO N/A
Growth
0 /100
Declining Book val. growth 18.34%
EPS growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor ROIC 49.23%
Asset turnover 0.00x
ROE 48.12%
Debt
69 /100
Low Debt/Equity 0.02x
Int. coverage -989.90x
Current ratio 7.14x
Stability
55 /100
Moderate Beta 0.75x
Profitable years 0
Rev. volatility 80.01%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o PTX.AX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
James McDonnell
Employees
3
Headquarters
Melbourne
Prihajajoči dogodki
19 FEB.
Earnings
Upcoming earnings report